Clinical Study

Serum Uric Acid as a Marker of Coronary Calcification in Patients with Asymptomatic Coronary Artery Disease with Preserved Left Ventricular Pump Function

Table 1

General characteristics of study patients.

All patients ( )

Age, years58.34 ± 9.60
Male, n (%)74 (58.7%)
Arterial hypertension, n (%)84 (66.7%)
Hyperlipidaemia, n (%)56 (44.4%)
2nd type diabetes mellitus, n (%)46 (36.5%)
Premature CAD in family anamnesis, n (%) 12 (9.5%)
Smoking, n (%)26 (20.6%)
eGFR, mL/min/m282.3 (95% CI = 58.7–102.6)
HbA1c, %6.8 (95% CI = 4.1–9.5)
Fasting glucose, mmol/L5.20 (95% CI = 3.3–9.7)
Creatinin, μmol/L86.74 (95% CI = 67.6–102.1)
Osteopontin, ng/mL43.55 (95% CI = 31.5–57.0).
Osteoprotegerin, pg/mL3849.51 (95% CI = 3282.23–4413.79).
hs-C-RP, mg/L4.95 (95% CI = 3.15–9.80)
TC, mmol/L5.1 (95% CI = 3.9–6.1)
LDL cholesterol, mmol/L3.23 (95% CI = 3.11–4.4)
HDL cholesterol, mmol/L0.91 (95% CI = 0.89–1.12)
Mean systolic BP, mm Hg130.90 ± 8.41
Heart rate, beat per min70.52 ± 3.34
LV EF, %42.80 ± 0.76
HD-NCP31 (95% CI = 21–56)
LD-NCP25 (95% CI = 13–48)
CAP96 (95% CI = 31–102)
Agatston’ score index586 (95% CI = 401–838)
Numerous coronary arteries with plaques determined
 1 vessel46 (36.5%)
 2 vessels42 (33.3%)
 3 vessels and more38 (30.2%)
ACEI/ARBs126 (100%)
Aspirin98 (77.8%)
Other antiaggregants6 (4.8%)
Statins94 (74.6%)
Metformin41 (32.5%)

CI: confidence interval, TC: total cholesterol, HbA1c: glycated hemoglobin, ACEI: angiotensin-converting enzyme inhibitor, ARBs: angiotensin-2 receptor blockers, HD-NCP: high-density noncalcified atherosclerotic plaque, LD-NCP: low-density noncalcified atherosclerotic plaque, and CAP: calcified atherosclerotic plaques.